Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enadenotucirev - Akamis Bio

Next Previous
Drug Profile

Enadenotucirev - Akamis Bio

Alternative Names: Ad11/Ad3 chimeric group B adenovirus; ColoAd-1; EnAd; Oncolytic Ad11/Ad3 chimeric group B adenovirus

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Akamis Bio; Bristol-Myers Squibb; Merck & Co; University of Oxford
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Renal cancer; Urogenital cancer
  • No development reported Cancer; Head and neck cancer; Ovarian cancer; Salivary gland cancer; Solid tumours

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in Colorectal-cancer(Late-stage disease, Metastatic disease) in United Kingdom (IV)
  • 26 Feb 2024 Efficacy data from a phase I trial in Cancer presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
  • 24 Feb 2023 PsiOxus Therapeutics completes a phase I trial for Colorectal cancer (Metastatic disease; Late-stage disease) in United Kingdom (NCT03916510)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top